Amgen Inc (AMGN) Financials
Key financial figures for Amgen Inc (Q3 2026).
Amgen Q3 2026 total revenues rose 8% to $10.37 billion and non-GAAP EPS rose 14% to $6.45, and full-year 2026 guidance was raised to $38.9-$39.7 billion in revenue. Total revenues were $10,365 million versus $9,557 million a year earlier (+8%); product sales rose 8% to $9,883 million, driven by volume growth, and seventeen products delivered at least double-digit sales growth. GAAP EPS rose 19% from $5.93 to $7.08 and non-GAAP EPS rose 14% from $5.64 to $6.45; GAAP operating income rose from $2,526 million to $3,710 million (37.5% of product sales) and non-GAAP operating income rose from $4,305 million to $4,676 million (47.3%). On the outlook: For full-year 2026 the company expects total revenues of $38.9 billion to $39.7 billion (previously $38.2 billion to $39.4 billion), GAAP EPS of $18.34 to $19.28 (previously $15.80 to $17.08) and non-GAAP EPS of $22.90 to $23.70 (previously $22.30 to $23.50), with a non-GAAP tax rate of 15.0% to 16.5%, capital expenditures of approximately $2.6 billion and share repurchases not to exceed $3.0 billion. Figures are for Q3 2026, as Amgen Inc. reported them.
- Revenue
- $10.4B
- Net Income
- $3.9B
- EPS
- $7.14
- Total Assets
- $96.0B
- Operating Cash Flow
- $4.2B
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q3 FY2026 | $10.4B | $3.9B | $7.08 | 35.79% | $3.7B |
| Q2 FY2026 | $10.1B | $2.4B | $4.37 | 34.95% | $3.5B |
| Q1 FY2026 | $8.6B | $1.8B | $3.34 | 30.94% | $1.5B |
| Q4 FY2025 | $9.9B | $1.3B | $2.45 | 39.83% | $961M |
| Q3 FY2025 | $9.6B | $3.2B | $5.93 | 26.43% | $4.2B |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $36.7B | $7.7B | $14.23 | 29.06% | $8.1B |
| FY2024 | $33.4B | $4.1B | $7.56 | 21.71% | $10.4B |
| FY2023 | $28.2B | $6.7B | $12.49 | 28.01% | $7.4B |
Frequently asked questions
What was Amgen Inc.'s revenue last quarter?
Amgen Inc. reported revenue of $10.37 billion for Q3 FY2026, up 8.5% from the same period a year earlier.
Is Amgen Inc. profitable?
Yes. Amgen Inc. reported net income of $3.86 billion for Q3 FY2026, a net margin of 37.28% on revenue.
How has Amgen Inc.'s margin trended?
Operating margin was 35.79% in Q3 FY2026, compared with 26.43% in the same period a year earlier. The quarter by quarter series is on the SentiSense financials page.
How much free cash flow did Amgen Inc. generate?
Amgen Inc. generated free cash flow of $3.65 billion in Q3 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for Amgen Inc on SentiSense, with up to forty quarters and twenty fiscal years of history.